Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohab Ibrahim

Pain Medicine Tucson, AZ Medical Doctor

NPI 1649433111 CMS profile 346683

1501 N Campbell Ave, Dept Of Anesthesiology, Tucson, AZ 85724

Open in the dashboard

General payments

$4,261

49 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$383,210 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Mohab Ibrahim of Tucson, AZ is reported in the CMS Open Payments database as having received $4,261 across 49 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $383,210 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 62nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $71 1
2024 General $368 6
2023 General $42 2
2022 General $1,636 10
2021 General $421 9
2020 General $802 8
2019 General $920 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohab Ibrahim
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Mohab Ibrahim were reported at $71. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Mohab Ibrahim Pain Medicine median Middle half National median
2019 $920 $498 $126–$1,682 $163
2020 $802 $284 $80–$910 $114
2021 $421 $399 $112–$1,219 $132
2022 $1,636 $455 $137–$1,484 $149
2023 $42 $484 $128–$1,495 $160
2024 $368 $498 $131–$1,540 $164
2025 $71 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $1,522 9 payments
  2. Boston Scientific Corporation $892 16 payments
  3. Relievant Medsystems, Inc. $815 5 payments
  4. Abbott Laboratories $713 13 payments
  5. Vertos Medical, Inc. $120 3 payments
  6. SI-BONE, Inc. $114 1 payment
  7. SPR Therapeutics, Inc $69 1 payment
  8. Stimwave Technologies Incorporated $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,312 10 payments
  2. Food and Beverage $1,948 39 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $1,522 9 payments
  2. Intracept Pain $520 1 payment
  3. SPECTRA WAVEWRITER $473 6 payments
  4. Neuromodulation-Research Only $350 4 payments
  5. Intracept Pain $295 4 payments
  6. Intracept Pain $295 4 payments
  7. Neuromodulation Dspsbls and Accs $188 2 payments
  8. ETERNA $97 3 payments
  9. mild Device Kit $75 2 payments
  10. ARTISAN $74 2 payments
  11. Other $415 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

92

Median for Pain Management: 951

Drug cost

$2,306

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 29 $735
Tizanidine Hcl Generic 21 $602
Pregabalin Generic 15 $597
Baclofen Generic 14 $346
Meloxicam Generic 13 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$39,840

Medicare's payments for the services billed

Medicare patients

157

Average age 74

Services billed

464

97 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Depression 34%
Osteoporosis 30%
Ischemic heart disease 29%
Diabetes 24%
Chronic kidney disease 23%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record